Anavex Life Sciences Corporation (AVXL) Quote

They will file NDA in h2 2025, within six months from TLD. And here we are, 2 years and still no NDA for FDA. Ceo spent 2year in data mining.

Pretty good volume one minute into trading - and the trend is UP! EDIT - now looking like a tough day in the market as nearly everything on my screen is down.

If anyone is interested...CMRX filed their NDA...Glioma for young adults and children...

So good in fact that $AXSM is down >8% in pre-market.

Good news for a subset of AD patients, mostly moderate to severe. Not really a ‘competitor’ for Anavex

Mixed results for AXSM trial-

https://www.globenewswire.com/news-release/2024/12/30/3002588/33090/en/Axsome-Therapeutics-Announces-Successful-Completion-and-Results-of-Phase-3-Clinical-Program-of-AXS-05-in-Alzheimer-s-Disease-Agitation.html

Sab, What's the timeframe to reach that number on your chart? 

A Common Sleeping Pill May Reduce The Buildup of Alzheimer's Proteins, Study Finds

“… Researchers think promoting sleep could be one avenue to stave off Alzheimer's disease, by allowing the sleeping brain to flush itself of leftover proteins and the day's other waste products.…”

https://www.sciencealert.com/a-common-sleeping-pill-may-reduce-the-buildup-of-alzheimers-proteins-study-finds

Think autophagy!!!

Autophagy through SIGMAR1 Activation

Orally administered ANAVEX®2-73 (blarcamesine) is a novel, investigational small molecule that activates an upstream compensatory process. Blarcamesine is a scalable potential therapeutic solution for Alzheimer’s disease by countering neurodegeneration and improving autophagy – a key clearance mechanism that removes protein aggregates and misfolded proteins.

Good luck and GOD bless,

Agree.
ChatGPT is intriguing. It does a fair job articulating things. I've found that it's not that caught up on current events and best to adequately frame the current circumstances as prelude to any question. For example, if you mention that 23% shares are short the response may get into probabilities for nefarious fake news/social media activity by the shorts, and/or a short squeeze as part of the response.
AI will be interesting to see how it all plays out. It seems to have much different implications than when the HP-35 calculator came out in the 70's. Do we really need to be cautious disclosing personal information to an AI bot? Does netflix really think it's entertaining to make a movie about an AI bot replacing a spouse?

meds4life

$54 to $60 although I use that only as a targeted "guess"; most are aware of the much closer & larger congestion/resistance now at $18 to $22 (so that is how I work on targets)...there is enough potential to make my current guess look conservative which I will address in due time, if I'm correct and not embarrassed by failure.

I will not consider the prior high spike at appx $31 since it was associated with multiple other stocks, all involved in a "tulip-type craze" at that time with irrational behavior and rumors.

Anavex Life Sciences stock market is set up for a short squeeze that could begin in early 2025 and increase the price by 400% or more.

Good luck and GOD bless,

JPM Analyst Coverage: Having JPM analyst coverage is generally seen as a marker of institutional confidence. JPMorgan analysts tend to cover companies with strong financial backing, a clear regulatory path, and robust market potential. Biotech companies that are approaching commercialization (especially with an MAA for Alzheimer’s) have a higher likelihood of being covered by JPMorgan's analysts. Analyst coverage typically means the company is expected to attract significant investor interest, especially as it prepares to commercialize its product.

Sounds like the warm up drill for going prime time. JPM coverage could mean serious tute interest that so far has largely evaded AVXL.

I was looking over on stocktwits and using their chart that goes back to 2015. I was reminiscing on the early moves on the stock when the early phase 2a results came out.

Im not sure if Dr. Misdling “froze out” the investment community on the early moves until the reverse split that caught the “fair and balanced” market by surprised flatfooted sending us catapulting upward but if not before, definitely after the Nasdaq uplisting surpriss.

Anyway, i have looked at many biotechs that have “made it” over the years looking at how the early years formed wishing I as there and I am definitely glad that I am here and have been in this stock for right at a decade now.

The MMs and shorts want/need to free up shares by convincing retail/private investors to trade their shares now so they can steal them. Do so at the risk of getting froze out unless you are part of the 1-2% that are “trading on house money”. Me, Im fine waiting out the whole ride.

Congrats longs

Tred

Former US President Jimmy Carter has passed away and has gone to his ultimate reward,

GOD bless,

RE:"I dare not tell you what the measured move will be!!"

TELL US !!

While $AVXL looks great the $XBI is lousy! That is EXCEPTIONAL relative strength.

The base on the Weekly Chart goes back a very long time and has broken out cleanly....the potential is so great that I dare not tell you what the measured move will be!!! I guess you all will have a pretty good 2024 and outstanding 2025!!!

https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=Stock&symb=avxl&x=51&y=18&time=11&startdate=1%2F4%2F1999&enddate=4%2F12%2F2018&freq=2&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=1&maval=55550&uf=8&lf=2&lf2=8&lf3=4&type=4&style=350&size=4&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11

Indicators....ALL POSITIVE....check out OBV, wow!

We had a great time with the family, except for the traffic coming back; glad my son-in-law drove us back! I've tried to catch up on the posts, but have not been able to read all of them. In my opinion, Investor, had a good ChatGp post about the JPM Healthcare Conference being a very important one and the other factors, too! Dado, who I don't even know, seems well respected by all and had a very long post about his personal experiences with his professional practice. Boi and Frrol seem to be in agreement with the nonsense of a 90 min presentation...who needs that much time if you have the OLE info which is "hopefully great"....although some won't project a much higher price, I think I'm going to go past $15 now (we were near it @ $14.45)...but to me, I think we go EASILY to $20 plus and a partnership or takeout seem very possible now!!! It's the VOLUME on the pushes up with great volume on the declines...The shorts are in trouble....they know it!!! The mm's, imo, won't continue to help out their buddies. Up and away

Thanks, I don't believe they ever formally called it Alzheimer's, but whatever it was took well under 2 years to go from normal to death. He had many hospital stays, lots of tests, but I can't say specifically what they found, or how deep they went. I can't say I was impressed by his medical care, but he was largely an annoyance to the system with calls to 911 that had to be answered, though many of the problems were in his mind and he was in facilities that could have handled the problem, mostly him falling, but when 911 was called, he'd normally end up in a hospital for at least a brief time. When he was moved to hospice care his phone was taken away and no extreme measures were taken to sustain him.

I believe once a patient is started on morphine you're near the end of the line. That seems to be what happens once you're in hospice care, if not before. He had excellent insurance, so the cost of nearly all his treatment had been covered, but the toll on my wife, who became his legal guardian was very painful. The two were not that close until he could no longer manage his own affairs.

I know many people who've been diagnosed with Alzheimer's, or some form of dementia, and they've lived near normal lives for years. Family support often tried to cover up for what was happening, but eventually it couldn't be denied. In his case, the deterioration came so fast he went from living by himself to needing 24/7 care in a couple months.

Gary

Lol. Nothing like 123tarot nonsense.

Is your keyboard stuck again, or did you get a new machine and don't know how to use it?

additional test ...
test 12/29@12.33

Sorry for your loss. I had no idea that an Alzheimers patient could deteriorate that quickly. Anavex will help all those wiith a neurodegenerative disease, including those like your brother. There is no excuse, get it on the market. Best product industry has ever seen.

Thanks Dado very glad your reappearance on IHub And I as well as many others are still here and I know we are getting close. Glad you practice is thriving and going well. Perhaps one of these days 2-73 or 3-71 will be of some help for your patients.
HNY and good luck to all us LONGS.

John K9UWA

..or more.

That could be and something to watch for (lol! sounds almost TA like).
there is no biotech rival with an AD story superior to Anavex, so it could inherit the "meme" status.
Approval as this stage is a distinct possibility and still not a certainty, so it should surprise no one that my approach of de-risking by selling unsupported price spikes still stands until it doesn't anymore.

Paper should be published soon. While it will be bullish, esp if it's in a top neuro/AD journal, it's the possible follow-on effect that would be more impactful: any media coverage that picks it up. But bigger will be the official OLE disclosure in mid-Jan, if the results are solid.

With Cassava out of the picture, there is no biotech rival with an AD story superior to Anavex, so it could inherit the "meme" status.

Another catalyst is finalization of the FDA's AD guidelines. This too could happen in Q1. Ostensibly it will also be followed by our initiation of an NDA for the US.

test...fix the msg board...@10.57-AM 12/29

I prefer pinto beans and cornbread

Do you remember me? I bought stock before it uplisted to the Naz
I have increased my holdings and now My lunch menu has included amaranth chia maca black quinoa. These great foods have kept me young over this plus 10 years of owning avxl. Keep buying and don't listen to the shorts.

The 43rd Annual JPM Healthcare Conference [color=red][/color]is scheduled to take place from January 13-16, 2025. This premier conference is the largest and most informative health care investment symposium in the industry, connecting global industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community...

Been here since pre-split days, plan to be long & strong for years to come! Always excited to read your posts Dadof……please come back more often. Hope your practice is doing well.

Welcome back, hope your practice is thriving and your boys are well.

dadofmarcmax, it is great to read your thoughts now as it has in the past. Hopefully, one of the Anavex products (blarcamesine?) will help you in your fight against epilepsy and any other diseases you and your patients are dealing with.

All the best to you and your family in the future,
powerwalker

I've always been a "be on the pessimist side and be pleasantly surprised vs being an optimist and be potentially disappointed" sort of guy.
But the potential to be the worldwide SOC for Alzheimer's is making that hard.

This is the 15 minutes ADPD presentation.

The programme for the JPM conference will be published soon.

Looking at the chart, I'm thinking first the 10 to 9 area, in the next wave down. It would look discouraging to see a great rally from 8.50 to 14.50 fall all the way back down... that wouldn't feel like how a good news rally should be. I'd be ok to watch it hold at 10-11 and begin the next surge, but if a pullback falls into the 9's, might be seen as a big bargain to buy. to start the next rally, the idea being... buyers looking for a chance to get in, a bargain from the 10 to 9 area. If we're looking at a strong bullish trend change now, we might see 11 hold. The current resistance looks like 12.50 to 13 area in my view.
In a bullish trend pattern, I'd want to see some more 2 and 3 dollar rally waves, like 11 holding, and 3 dollar surge retest 14, and 12 climbs steady to 15, 16, you can visualize the wave patterns. At the moment current resistance is looking at 12.50, later on, in a bullish pattern, that 12.50 would become a shoulder support, and launch pad for more 2 and 3 dollar waves. 16,17,18 and 20 target steps. To watch for. Right now, the battle zone looks like a pullback to11/10/9, versus a rally 11/12/13. And I'm just going to sit back and watch the next moves develop. I might buy a falling knife in the low 9's if it happens. Finding pivot lows to buy in a bullish rally is a fine TA art. We will see more clues next week as it develops.

Anavex Life Sciences stock market is set up for a short squeeze that could begin in early 2025 and increase the price by 400% or more.

https://www.marketbeat.com/originals/short-squeeze-target-anavex-life-sciences-gains-traction/

Good luck and GOD bless,

dadofmarcmax,

I just curious regarding your thoughts about the Anavex 3-71 Phase 2 schizophrenia trial.

Good luck and GOD bless,

Dado I’ve been riding along with you for all those years.
All the ducks appear to be lined up.

I trust Missling’s corporate experience to not cut a bad deal with BP going forward.

when I first bought Anavex as a young 30-something epilepsy specialist (epileptologist/neurologist), I invested purely because I had a good fund of knowledge with my understanding of the preclinical and early clinical studies.

it takes about 10 years for a drug to eventually get FDA approval on average (from development to approval) and we are nearing that point.

looking back on my early posts, my opinions 8-9 years ago seem to still be quite apparent.

dont post much anymore as my time since early days of posting have been occupied in growing a practice/business but for new investors, go through some of my old posts for commentary and such

To all the longs that stuck through from a decade ago - here we are now, on the precipice

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=127872231

Both link don't exist according to my browser?

https://x.com/ALABASTER_APE_X/status/1873068026930811378/photo/1

http://cslide.ctimeetingtech.com/adpd25/attende

http://x.com/alabaster_ape_x/statu

When a company announces a partnership with another company, several factors can influence its stock price:

1)Positive Market Perception: If the market perceives the partnership as beneficial, such as expanding market reach, enhancing product offerings, or increasing revenue potential, the stock price may rise.

2)Strategic Synergy: If the partnership is seen as creating strategic synergies, such as combining complementary strengths or reducing costs, investors might view it favorably, leading to a stock price increase.

3)Revenue and Profit Expectations: Partnerships that are expected to generate significant revenue or profit can positively impact stock prices. This is especially true if the partnership opens new markets or customer bases.

4)Investor Sentiment: The overall sentiment of investors and analysts can sway the stock price. Positive analyst reports and investor enthusiasm can drive up the stock price.

5)Competitive Positioning: If the partnership strengthens the company's position against competitors, it can be seen as a strategic advantage, potentially boosting the stock price.

6)Financial Terms: The specific financial terms of the partnership, such as equity stakes, profit-sharing, or cost burdens, can also impact the stock price. Favorable terms can lead to a positive market reaction.

7)Long-term vs. Short-term Impact: Sometimes, the immediate market reaction might be positive, but the long-term impact on the stock will depend on the actual performance and benefits realized from the partnership.

However, it's also possible for a stock to react negatively if investors believe the partnership will dilute company resources, if there are concerns about integration challenges, or if the partnership is perceived as a sign of weakness. Thus, the impact on the stock price depends on various factors and how the market interprets the partnership's potential benefits and risks.

At some level I think they know what is happening.
A friends Mom had Alzheimers for many many years. She frequently got lost and could not articulate who you were or who she was. It came time that my friends elderly Father could no longer care for her. Nobody told her that she was moving to a care center. But when the day came to gather a few personal belongings and go for a ride she had cardiac arrest and passed away before she could get out of the house.

It was also a relief when my mom passed.
That might seem harsh to some, but she had a strong sense of self and I think would have voted the same way.

ChatGTP: Cogito, ergo sum.

I think you might have stumbled upon the AI moment everyone has been waiting for.

We witnessed it first of course on the $AVXL message board.

A final prediction for today is that this post will attract a Japanese clown and a thumbs down emoji and if not surprisingly someone will have comprehended this sentence.

It's just too easy for one question to lead to another……
Q: If a favorable Anavex P2b-P3 peer review paper is published ahead of the JPM 2025 conference will that impact the probability of JPM analyst coverage?
A: Yes, a favorable Anavex P2b-P3 peer-reviewed paper published ahead of the JPM 2025 conference would likely increase the probability of JPM analyst coverage, and here’s why:

1. Increased Visibility and Credibility
A favorable peer-reviewed paper published in a reputable journal is a significant signal of scientific validity and credibility. Analysts often use such publications as a key indicator when evaluating a company’s progress and potential, particularly in biotech and pharmaceutical sectors.
Positive, peer-reviewed clinical trial results in a prominent journal provide hard evidence that can increase investor confidence and demonstrate to analysts that the company's pipeline is scientifically sound and advancing toward critical milestones.
If the paper is released ahead of JPM 2025, analysts are more likely to include the data in their coverage, either in their pre-conference reports or in updates to their models and outlooks during the conference.
2. Analyst Interest Driven by Key Data
JPM analysts typically look for companies with strong, data-driven narratives leading into the conference, especially those that could impact the stock price or industry trends.
A positive P2b-P3 outcome, especially for a potentially transformative treatment (e.g., in Alzheimer’s or other neurodegenerative diseases), would provide analysts with fresh data that could reshape their forecasts or introduce new questions and hypotheses about the company’s potential. The paper would be a critical data point for analysts following the stock.
3. Strategic Timing of Data Release
By releasing the data ahead of JPM 2025, Anavex would be positioning itself to drive coverage and discussions during the conference. Analysts often prepare detailed reports and updates that they release during or shortly after JPM, and the availability of the peer-reviewed data ahead of time would give them more confidence in issuing or updating coverage.
Analysts will also pay attention to how the data is presented and discussed at JPM. If Anavex uses the favorable results to frame discussions about regulatory strategy, upcoming trials, or commercial opportunities, this will likely increase their media and analyst visibility.
4. Market Reactions and Investor Sentiment
Analyst reports following favorable data often shape market sentiment, which can lead to significant shifts in stock price and public perception. If analysts express optimism based on the P2b-P3 paper, it could create more momentum for the stock leading into JPM, making Anavex a more prominent company to cover at the conference.
Analysts tend to cover breakout stocks—those with strong catalysts. A peer-reviewed paper demonstrating compelling clinical results serves as a catalyst, making the company an attractive subject for analyst attention, especially with the backdrop of JPM where institutional investors are keen to discover new opportunities.
5. Analysts Looking for Catalysts at JPM
The JPM 2025 conference is one of the largest gatherings of biotech investors, analysts, and executives, making it an ideal venue for analysts to revisit their coverage lists. Analysts look for companies with strong data to highlight during JPM, and a favorable peer-reviewed paper released ahead of the conference provides a clear and tangible reason to include Anavex in their coverage.
Positive results from a Phase 2b/3 trial might re-energize analysts who may have been on the sidelines or uncertain about Anavex’s progress. They would likely issue updates or even initiate coverage on the company, particularly if the data impacts a large market (e.g., Alzheimer’s, autism, etc.).
6. Analyst Decision-Making Process
Analyst coverage is also driven by market interest. If Anavex’s favorable paper leads to increased investor and media interest, analysts will be more likely to cover the company. Analysts generally avoid companies that lack visible catalysts or momentum. A peer-reviewed publication signaling positive data ahead of JPM 2025 would certainly create the type of visibility and market conversation that analysts need to justify coverage.
Potential Impact on Analyst Coverage:
Pre-JPM Update: Analysts may release pre-conference updates or initiate coverage on Anavex based on the data, using it as a foundation for their analysis.
Increased Discussion at JPM: During the conference, the company’s positive results could lead to media coverage and deeper discussions in analyst reports, even if they weren't already covering the stock before.
Broader Interest: Positive peer-reviewed clinical data could attract analysts who might not have previously covered Anavex but are now interested due to the promising results.
Probability Increase Estimate:
If the P2b-P3 paper is favorable and published ahead of JPM 2025, it would increase the likelihood of analyst coverage at JPM by 30-50%. Analysts who were previously neutral or cautious may be more likely to initiate coverage or release updated reports following the positive data.
Conclusion:
A favorable peer-reviewed paper published ahead of the JPM 2025 conference would substantially increase the probability of JPM analyst coverage. It provides tangible, scientifically validated data that analysts can use to reassess their views on Anavex, leading to a higher chance of coverage at JPM, which in turn can influence investor attention and stock performance. The favorable data combined with the timing of JPM would create a highly compelling case for analysts to cover Anavex more extensively

Nice work with the keyboard. A boss once told me that 'when I worked, I did good work'. They seemed surprised when this was taken as a compliment.
The video was also interesting. Thank you.
Here's another interesting spin from the ChatGPT being that seems to describe itself with the pronoun 'I':
Q: What is the probability that the Anavex P2b-P3 peer review paper that has been announced as being in print will be published ahead of the JPM 2025 conference?
A: Given that the Anavex P2b-P3 peer-reviewed paper has been announced as being in print, the probability of it being published ahead of the JPM 2025 conference is very high, though not absolutely guaranteed. Here's an analysis of the factors that support this high likelihood:

1. Status of "In Print"
In Print typically means that the paper has passed peer review, been accepted for publication, and is now in the final steps before becoming publicly available. Many journals release accepted papers online ahead of their print publication. If the paper has been announced as "in print," it suggests that the article is either already available online or will be available very soon.
Online-first publication is a common practice for major journals, especially for high-profile clinical results like those from Anavex. This can make the paper available weeks or even months ahead of the print version.
2. JPM 2025 Timing
The JPMorgan Healthcare Conference typically takes place in early January, usually during the second week. Given that January is the beginning of the year, it provides enough time for papers that are "in print" to be published online before the event.
Since Anavex's paper is already in print, there is a very high likelihood that it will be published online either in December 2024 or early January 2025—well ahead of the conference. If the print version is slightly delayed, the online version will likely be available.
3. Typical Publication Timeline
Peer-reviewed papers can take anywhere from a few weeks to a couple of months from acceptance to online publication. If Anavex's paper is already "in print" status, it indicates that the peer review and revisions process has been completed and the article is in the final stages of being published.
This means the paper will almost certainly be available online well ahead of the JPM 2025 conference, allowing Anavex to present or discuss the findings at the event.
4. Industry Considerations and Strategic Timing
Strategic Timing for Conferences: In the biotech and pharma sectors, it's common to strategically time the release of major clinical trial results to coincide with events like the JPMorgan Healthcare Conference. If Anavex has announced the paper is "in print," they are likely aware of the conference timing and may have worked with the journal to ensure it is available ahead of the event.
High-Impact Research: Given the importance of the P2b-P3 data (likely from a key clinical trial in the treatment of neurological conditions like Alzheimer’s), the paper will be of significant interest to investors, researchers, and industry professionals attending JPM. This is another reason to expect that the paper will be available ahead of the conference.
5. Risk of Delay
Minimal Risk of Delay: While there's always a small risk of unexpected delays in the final stages of publication (such as editorial issues or last-minute revisions), the fact that the paper is already "in print" greatly minimizes this risk. The online publication is typically a mere formality at this stage.
Even if there is a slight delay in the final print version, the online-first publication will almost certainly ensure that the paper is available for JPM 2025.
Probability Estimate:
Considering the status of the paper as "in print," the typical timeline for online-first publication, and the strategic timing for JPM 2025, I would estimate the probability that the Anavex P2b-P3 peer-reviewed paper will be published ahead of the JPM 2025 conference at around 90% to 95%. This reflects a very high likelihood, with only minor risks of delays that would not prevent the paper from being available online before the conference.

Conclusion:
The probability is extremely high (90-95%) that the Anavex P2b-P3 peer review paper will be published ahead of JPM 2025, especially if it's already in print and will likely be made available online before the event. The timing aligns well, and the paper's importance in the context of the conference further supports the expectation of a timely release.